Business
Advicenne Raises 2.6 Million Euros in Its Capital Increase and Extends Its Financial Visibility
PARIS, July 21, 2025--Regulatory News: Advicenne (Euronext Growth® - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases (the "Company"), raised a total of nearly €2.6 million through the issue of 1,895,948 New Shares at a unit price of €1.35 as part of the capital increase through the issue of new ordinary shares (the "New Shares") with shareholders' pre-emptive subscription rights
About this update from Advicenne Sa
[{"type":"list","items":[{"val":[{"type":"text","content":"Subscription of €2.6 million, representing 100% of the initial amount","length":69,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Financial horizon extended to the end of Q3 2026 thanks to concomitant financial restructuring","length":94,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Bpifrance now holds 23.95% of capital and 28.05% of voting rights.","length":66,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":229,"olType":false},{"type":"text","content":"PARIS, July 21, 2025--(BUSINESS WIRE)--Regulatory News:","length":55,"tagName":"p"},{"type":"text","content":"Advicenne (Euronext Growth® - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases (the "Company"), raised a total of nearly €2.6 million through the issue of 1,895,948 New Shares at a unit price of €1.35 as part of the capital increase through the issue of new ordinary shares (the "New Shares") with shareholders' pre-emptive subscription rights (the "DPS") announced on June 30, 2025. This transaction will extend financial visibility until the end of the third quarter of 2026.","length":628,"tagName":"p"},{"type":"text","content":"Didier Laurens, Chief Executive Officer of Advicenne, comments: "I would like to extend my warmest thanks to the shareholders who, through this operation, are supporting Advicenne's continued development, first and foremost Bpifrance. We can be proud of their confidence in the project supported by all Advicenne employees. This transaction puts the finishing touches to the optimization of our financing. Now, more than ever, we are focusing on the upcoming filing of ADV7103 for registration in the dRTA in the United States, and the extension of our financial visibility enables us to project ourselves calmly towards this objective."","length":651,"tagName":"p"},{"type":"text","content":"Philippe Boucheron, Deputy Director, Biotech and Medtech Investment Division of Bpifrance and Chairman of Advicenne, highlights: "We were keen to support Advicenne and its team. Opportunities to invest in a commercial company in our sector which has developed its own drug from lab to market are rare, particular...